[Form 4] VOYA FINANCIAL, INC. Insider Trading Activity

Rhea-AI Filing Summary

Rockwell Medical, Inc. (RMTI) – Form 4/A amendment reports that Senior Vice President & Chief Financial Officer Jesse Neri sold 886 common shares on 01-Jul-2025 at a weighted-average price of $0.82 per share. The filing clarifies that the trade was executed pursuant to a Rule 10b5-1 trading plan adopted on 13-Dec-2024; this checkbox was inadvertently left blank in the original Form 4 filed 02-Jul-2025.

After the disposition, Neri directly owns 126,614 shares of RMTI. No derivative securities were bought or sold, and there are no other changes to his ownership stake.

The transaction represents roughly 0.7 % of the executive’s reported holdings and is immaterial relative to the company’s total shares outstanding. Because the sale was pre-arranged and the amendment is purely administrative, the filing carries limited fundamental significance but may still interest investors who monitor insider activity for sentiment cues.

Positive

• None.

Negative

• Insider sale by CFO: Although small (886 shares), any executive selling can be viewed cautiously by sentiment-focused investors.

Insights

Corporate Governance Analyst

TL;DR Minor insider sale under 10b5-1 plan; administrative amendment; neutral investor impact.

The amended Form 4 simply documents that the 886-share sale by CFO Jesse Neri occurred within a pre-scheduled Rule 10b5-1 framework, mitigating any concerns about opportunistic timing. The disposal equals less than 1 % of his holdings and is insignificant compared with Rockwell Medical’s float. No new economic transactions or derivative positions are disclosed, and beneficial ownership remains sizable at 126,614 shares. Given the small volume and procedural nature of the amendment, I view the event as neutral for valuation and governance risk assessments.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Katz Michael Robert

(Last) (First) (Middle)

200 PARK AVENUE

(Street)

NEW YORK NY 10166

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Voya Financial, Inc. [ VOYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2025		M		1,679	A	$0(1)	39,259	D
Common Stock	07/01/2025		F		765	D	$72.51	38,494	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	07/01/2025		M			1,679	(2)	(2)	Common Stock	1,679	$0	20,998	D
Performance Stock Unit	(3)							(3)	(3)	Common Stock	46,170		46,170	D
Deferred Savings Plan Issuer Stock Units	(4)							(4)	(4)	Common Stock	847.647		847.647	D
Performance-Based Stock Options	(5)							(5)	(5)	Common Stock	56,187		56,187	D

Explanation of Responses:

1. Delivery of shares of the Company's common stock was made to the reporting person without the payment of any consideration in connection with the vesting of the underlying restricted stock units that were awarded as compensation.

2. The restricted stock units were awarded as compensation and converted to common stock on a 1 to 1 basis upon the vesting date.

3. The performance stock units were awarded as compensation and converted to common stock based on the achievement of certain performance factors.

4. Each of these units represents a right to receive the cash value of one share of the company's common stock upon the reporting person's separation from the company. The reporting person may reallocate investments in the units to alternative investments in the future.

5. The options vest based on the conditions set forth in their respective agreements.

Remarks:

Executive Vice President, Chief Financial Officer

	/s/ Julie Watson, Attorney-in-Fact	07/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Rockwell Medical (RMTI) shares did CFO Jesse Neri sell?

He sold 886 common shares on 01-Jul-2025 at a weighted-average price of $0.82.

What is the CFO’s remaining ownership after the transaction?

Following the sale, Jesse Neri directly owns 126,614 RMTI shares.

Was the sale executed under a Rule 10b5-1 trading plan?

Yes. The Form 4/A confirms the sale was made pursuant to a Rule 10b5-1 plan adopted on 13-Dec-2024.

Does the Form 4/A disclose any derivative securities transactions?

No. No options, warrants, or other derivatives were acquired or disposed of in this filing.

Why was the Form 4 amended?

The amendment checks the box indicating the sale was under a 10b5-1 plan; no economic details were changed.